Close

Ratings by Goldman Sachs (Chris Shibutani)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
9/27/2022 Arcutis Biotherapeutics Inc. ARQT Maintain Buy
(N/A)
 
 
  Details
9/22/2022 Revance Therapeutic RVNC New Coverage Buy
(N/A)
25.80
(30.19)
17.02% Details
9/8/2022 Amylyx Pharmaceuticals inc. AMLX Maintain Neutral
(N/A)
 
 
  Details
8/15/2022 Entrada Therapeutics TRDA Maintain Neutral
(N/A)
 
 
  Details
8/12/2022 Prometheus Biosciences Inc RXDX Maintain Buy
(N/A)
 
 
  Details
8/9/2022 BioNTech BNTX Maintain Neutral
(N/A)
 
 
  Details
8/3/2022 Kymera Therapeutics KYMR New Coverage Buy
(N/A)
21.48
(20.69)
-3.68% Details
7/20/2022 Inova Technology, Inc. INVA New Coverage Neutral
(N/A)
14.51
(12.37)
-14.75% Details
7/20/2022 Prometheus Biosciences Inc RXDX New Coverage Buy
(N/A)
29.29
(56.22)
91.94% Details
7/6/2022 Amylyx Pharmaceuticals inc. AMLX Maintain Neutral
(N/A)
 
 
  Details
6/13/2022 EQRx, Inc. EQRX New Coverage Buy
(N/A)
4.10
(5.05)
23.17% Details
6/6/2022 Arcutis Biotherapeutics Inc. ARQT Maintain Buy
(N/A)
 
 
  Details
5/13/2022 Entrada Therapeutics TRDA Maintain Neutral
(N/A)
 
 
  Details
4/27/2022 Organon & Co. OGN New Coverage Buy
(N/A)
31.66
(24.39)
-22.96% Details
4/27/2022 Royalty Pharma RPRX New Coverage Buy
(N/A)
41.83
(41.27)
-1.34% Details
4/20/2022 Johnson & Johnson JNJ Maintain Neutral
(N/A)
 
 
  Details
4/20/2022 Alkermes ALKS New Coverage Buy
(N/A)
28.48
(22.69)
-20.33% Details
4/18/2022 Nektar Therapeutics NKTR Downgrade Sell
(Neutral)
6.16
(3.30)
-46.43% Details
4/1/2022 Amylyx Pharmaceuticals inc. AMLX Downgrade Neutral
(Buy)
14.93
(33.17)
122.17% Details
3/31/2022 BioNTech BNTX Maintain Neutral
(N/A)
 
 
  Details
3/29/2022 Tango Therapeutics Inc. TNGX Maintain Buy
(N/A)
 
 
  Details
3/17/2022 Arcutis Biotherapeutics Inc. ARQT New Coverage Buy
(N/A)
15.98
(19.77)
23.72% Details
3/17/2022 Repare Therapeutics RPTX New Coverage Buy
(N/A)
12.12
(12.95)
6.85% Details
3/1/2022 Revolution RVMD Maintain Neutral
(N/A)
 
 
  Details
2/25/2022 Neurocrine Bio. NBIX Upgrade Buy
(Neutral)
85.55
(111.12)
29.89% Details
2/7/2022 Bristol-Myers Squibb Co. BMY Maintain Buy
(N/A)
 
 
  Details
2/3/2022 Abbvie ABBV Maintain Neutral
(N/A)
 
 
  Details
2/1/2022 Amylyx Pharmaceuticals inc. AMLX New Coverage Buy
(N/A)
20.00
(14.93)
-25.35% Details
1/26/2022 Johnson & Johnson JNJ Maintain Neutral
(N/A)
 
 
  Details
12/17/2021 Abbvie ABBV New Coverage Neutral
(N/A)
131.78
(138.71)
5.26% Details
12/17/2021 Pfizer PFE New Coverage Neutral
(N/A)
61.25
(42.44)
-30.71% Details
12/17/2021 Eli Lilly LLY New Coverage Neutral
(N/A)
279.04
(330.10)
18.3% Details
12/17/2021 Johnson & Johnson JNJ New Coverage Neutral
(N/A)
173.01
(160.84)
-7.03% Details
12/17/2021 Bristol-Myers Squibb Co. BMY New Coverage Buy
(N/A)
62.17
(70.06)
12.69% Details
12/17/2021 Merck MRK New Coverage Conviction Buy
(N/A)
75.91
(87.77)
15.62% Details
11/23/2021 Entrada Therapeutics Inc. TRDA New Coverage Neutral
(N/A)
32.79
(14.84)
-54.74% Details
11/11/2021 BioNTech BNTX Maintain Neutral
(N/A)
 
 
  Details
11/2/2021 Neurocrine Bio. NBIX Maintain Neutral
(N/A)
 
 
  Details
10/26/2021 Exscientia PLC EXAI New Coverage Buy
(N/A)
22.20
(8.59)
-61.31% Details
9/7/2021 Tango Therapeutics Inc. TNGX New Coverage Buy
(N/A)
12.00
(4.12)
-65.67% Details
8/12/2021 Revolution RVMD Downgrade Neutral
(Buy)
26.90
(19.40)
-27.88% Details
8/11/2021 BioNTech BNTX Maintain Neutral
(N/A)
 
 
  Details
7/23/2021 Seres Therapeutics MCRB Downgrade Sell
(Neutral)
20.83
(7.12)
-65.82% Details
5/18/2021 Exelixis EXEL New Coverage Sell
(N/A)
25.24
(15.39)
-39.03% Details
5/18/2021 Seres Therapeutics MCRB New Coverage Neutral
(N/A)
21.80
(7.12)
-67.34% Details
5/18/2021 Neurocrine Bio. NBIX New Coverage Neutral
(N/A)
93.08
(85.55)
-8.09% Details
5/18/2021 Nektar Therapeutics NKTR New Coverage Neutral
(N/A)
18.19
(3.30)
-81.86% Details
5/18/2021 BioNTech BNTX New Coverage Neutral
(N/A)
198.30
(137.25)
-30.79% Details
5/18/2021 Revolution RVMD New Coverage Buy
(N/A)
31.48
(19.40)
-38.37% Details
5/18/2021 Arena Pharma ARNA New Coverage Buy
(N/A)
60.89
(99.98)
64.2% Details